The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...